- Raw materials
- Antifungals
- Pramiconazole
Pramiconazole API Manufacturers & Suppliers
0 verified results
All Pramiconazole data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Pramiconazole | CAS No: 219923-85-0 | GMP-certified suppliers
A medication that targets fungal and skin conditions including seborrhea, onychomycosis, and other dermatological infections, currently under clinical investigation.
Primary indications
- Investigated for use/treatment in seborrhea, fungal infections, skin infections/disorders, and onychomycosis
Product Snapshot
- Pramiconazole is an oral small molecule antifungal agent
- It is primarily investigated for the treatment of seborrhea, fungal infections, skin disorders, and onychomycosis
- The compound is currently in the investigational stage and has not received regulatory approval
Clinical Overview
Although detailed pharmacodynamic data and mechanism of action have not been fully disclosed, pramiconazole, by class association, is inferred to exert antifungal activity potentially through inhibition of fungal cytochrome P450-dependent 14α-demethylase. This enzyme is critical for ergosterol biosynthesis, an essential component of fungal cell membranes, suggesting disruption of membrane integrity and fungal growth suppression.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for pramiconazole remain to be comprehensively characterized. As an investigational agent, data on systemic bioavailability, metabolic pathways, and elimination half-life are limited or unpublished. Safety and toxicity profiles have not been formally established; therefore, caution is warranted in interpretation of tolerability and adverse event potential until clinical trial data become available.
Pramiconazole is not approved by major regulatory agencies for any clinical use and remains under clinical investigation. Its current usage context is limited to research settings assessing efficacy and safety in fungal-related dermatological conditions.
For pharmaceutical formulation scientists and API sourcing professionals, the sourcing of pramiconazole API necessitates stringent quality control measures given its investigational status. Purity, polymorphic form, and chemical stability should be verified according to International Conference on Harmonisation (ICH) guidelines. Suppliers must provide comprehensive analytical data, including impurity profiles, to support regulatory submission requirements and ensure batch-to-batch consistency for clinical trial material production.
Identification & chemistry
| Generic name | Pramiconazole |
|---|---|
| Molecule type | Small molecule |
| CAS | 219923-85-0 |
| UNII | 4SYH0R661F |
| DrugBank ID | DB06295 |
Formulation & handling
- Pramiconazole is a poorly water-soluble small molecule, requiring formulation strategies to enhance bioavailability for oral administration.
- Its high LogP indicates significant lipophilicity, suggesting potential use of lipid-based or solubilizing excipients.
- As an investigational phenylpiperazine derivative, stability under standard conditions should be confirmed, with attention to moisture and light exposure during handling.
Regulatory status
Pramiconazole is a type of Antifungals
Antifungals are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) designed to combat fungal infections. These medications are developed to target and eliminate fungi, including yeasts and molds, which can cause a range of diseases in humans and animals.
Antifungals work by interfering with specific components or processes essential for fungal growth and reproduction. They may inhibit the synthesis of fungal cell walls or disrupt the production of ergosterol, a crucial component of fungal cell membranes. By targeting these key mechanisms, antifungal APIs effectively hinder the growth and spread of fungal infections.
The diversity within the antifungal category is reflected in the various classes of antifungal APIs available. Azoles, polyenes, echinocandins, and allylamines are common classes of antifungals. Each class exhibits unique mechanisms of action and targets specific types of fungi. This diversity enables healthcare professionals to tailor treatment plans to the specific fungal infection, optimizing therapeutic outcomes.
Antifungal APIs find application in various pharmaceutical formulations, including oral medications, topical creams, ointments, and intravenous solutions. They are crucial for the treatment of common fungal infections like athlete's foot, ringworm, vaginal yeast infections, and oral thrush. Additionally, antifungals play a crucial role in managing serious systemic fungal infections that can pose significant health risks, especially in immunocompromised individuals.
Overall, antifungal APIs are indispensable tools in the fight against fungal infections, offering effective treatment options and improving the quality of life for patients suffering from these conditions. With ongoing research and development, the antifungal category continues to evolve, providing innovative solutions to combat the ever-changing landscape of fungal pathogens.
